Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.
Authors
Van K. Morris II
MD Anderson Cancer Center, Houston, TX;
Van K. Morris II, Katherine A Guthrie , Scott Kopetz , Rimini Breakstone , Thomas Benjamin Karasic , Zishuo Ian Hu , Shay Bellasea , Marwan Fakih , Sepideh Gholami , Philip Jordan Gold , Philip Agop Philip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05308446
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS265)
DOI
10.1200/JCO.2023.41.4_suppl.TPS265
Abstract #
TPS265
Poster Bd #
P7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
First Author: Van K. Morris II
Poster
2024 ASCO Gastrointestinal Cancers Symposium
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
First Author: Van K. Morris II
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.
First Author: Chetan Vakkalagadda
Poster
2016 ASCO Annual Meeting
Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
First Author: Josep Tabernero